TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
TENecteplase in Central Retinal Artery Occlusion (TenCRAOS): A Prospective,
randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25
mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomization).
A Prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial
of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomization). At all
participating centers, ophthalmologists are involved in the diagnosis and visual outcome
measurements using a standardized protocol. The patients will be promptly examined by the
ophthalmologist. As soon as the CRAO is diagnosed by the ophthalmologist, the patients will
be managed in the stroke unit during treatment, monitoring, and medical investigations. After
treatment in the stroke unit, the patients will be re-examined by an ophthalmologist and a
neurologist as an out-patient at (30 ±5) and 90 (±15) days